FDA To Tighten Up Regulations On Anticancer Drug Combinations, Stop “Permissiveness”
In Brief: Shingleton Chairs Cancer Control Committee; Joftes, Price Head Review, Organ Site Branches
NDA For MeCCNU Turned Down By Oncologic Drugs Advisory Committee
Schepartz New DCT Deputy Director; DeVita To Continue As Clinical Director
Nine Cancer Act Changes Considered By NCAB Subcommittee
Trending Stories
- Abdallah Abou Zahr, an oncologist whose cancer story resonated widely, dies of liposarcoma at 42
- Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched - Supportive cancer care is the smart investment our leaders in Washington can’t afford to ignore
- Fifth time’s a charm? Mikaela Naylon Give Kids a Chance Act is included in FY26 spending bill
- On Day 2 as director of NYU Perlmutter, Anirban Maitra talks about the advantages of running a matrix cancer center
- Letai: NCAB’s ad hoc working group plays major role in advising NCI on extramural research
The group replaced the NCI Board of Scientific Advisors









